Arcutis Announces Proposed Public Offering

Company Overview - Arcutis Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on immuno-dermatology innovations [5] - The company has a growing portfolio that includes two FDA-approved products and a robust pipeline targeting inflammatory dermatological conditions such as scalp and body psoriasis, atopic dermatitis, and alopecia areata [5] Public Offering Announcement - Arcutis announced a public offering of $150 million in common stock and pre-funded warrants, with an additional 30-day option for underwriters to purchase up to $22.5 million more [1][2] - The offering is subject to market conditions and there is no assurance regarding its completion or terms [1] Underwriters and Registration - Morgan Stanley, TD Cowen, and Guggenheim Securities are the joint lead bookrunning managers for the offering, with Mizuho and Needham & Company as co-lead managers [2] - The securities are being offered under an effective shelf registration statement filed with the SEC on January 31, 2024 [2]